Cyramza 10 mg/ml concentrate for solution for infusion

  • Name:

    Cyramza 10 mg/ml concentrate for solution for infusion

  • Company:
    info
  • Active Ingredients:

    Ramucirumab

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 02/10/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 2/10/2019

Click on this link to Download PDF directly

Eli Lilly and Company (Ireland) Limited

Eli Lilly and Company (Ireland) Limited

Company Products

Medicine NameActive Ingredients
Medicine Name ABASAGLAR 100 units/mL solution for injection in cartridge Active Ingredients Insulin glargine
Medicine Name ABASAGLAR 100 units/mL solution for injection in pre-filled pen Active Ingredients Insulin glargine
Medicine Name Adcirca Active Ingredients Tadalafil
Medicine Name Alimta Active Ingredients Pemetrexed disodium
Medicine Name Cialis 10mg Tablets Active Ingredients Tadalafil
Medicine Name Cialis 2.5mg Tablets Active Ingredients Tadalafil
Medicine Name Cialis 20mg Tablets Active Ingredients Tadalafil
Medicine Name Cialis 5mg Tablets Active Ingredients Tadalafil
Medicine Name Cymbalta Active Ingredients duloxetine hydrochloride
Medicine Name Cyramza 10 mg/ml concentrate for solution for infusion Active Ingredients Ramucirumab
Medicine Name Forsteo Active Ingredients Teriparatide
Medicine Name Humalog 100 units/ml Junior KwikPen, solution for injection in a pre-filled pen Active Ingredients Insulin lispro
Medicine Name Humalog 100 units/ml Kwikpen soluton for injection Active Ingredients Insulin lispro
Medicine Name Humalog 100 units/ml, solution for injection in cartridge (3ml) (insulin lispro) Active Ingredients Insulin lispro
Medicine Name Humalog 100 units/ml, solution for injection in vial Active Ingredients Insulin lispro
Medicine Name Humalog 200 Units/ml KwikPen, solution for injection in pre-filled pen Active Ingredients Insulin lispro
Medicine Name Humalog Mix25 100 units/ml Kwikpen suspension for injection Active Ingredients Insulin lispro
Medicine Name Humalog Mix25 100 units/ml suspension for injection in cartridge Active Ingredients Insulin lispro
Medicine Name Humalog Mix50 100 units/ml Kwikpen suspension for injection Active Ingredients Insulin lispro
Medicine Name Humalog Mix50 100 units/ml suspension for injection in cartridge Active Ingredients Insulin lispro
Medicine Name Humulin I (Isophane), 100IU/ml suspension for injection in cartridge Active Ingredients Insulin human
Medicine Name Humulin I (Isophane), 100IU/ml suspension for injection in vial Active Ingredients Human Insulin
Medicine Name Humulin I KwikPen 100 IU/ml suspension for injection Active Ingredients Human Insulin
Medicine Name Humulin M3 (Mixture 3), 100IU/ml suspension for injection in cartridge Active Ingredients Insulin human
Medicine Name Humulin M3 (Mixture 3), 100IU/ml suspension for injection in vial Active Ingredients Insulin human
1 - 0 of 41 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 2 October 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4          Special warnings and precautions for use

 

Aneurysms and artery dissections
The use of VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysms and/or artery dissections. Before initiating Cyramza, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.

 

 

4.8          Undesirable effects

 

ADRs of aneurysms and artery dissections have a frequency of ‘not known’.

 

 

10.      DATE OF REVISION OF THE TEXT

 

               26 September 201930 September 2019

 

 

CZ8MCZ9M

Updated on 2 October 2019 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects

Updated on 30 September 2019 PIL

Reasons for updating

  • Change to section 2 - driving and using machines
  • Change to section 3 - how to take/use
  • Removal of Black Inverted Triangle

Updated on 30 September 2019 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text
  • Removal of Black Inverted Triangle

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

 

2.         QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Excipient with known effect:

 

 

4.2             Posology and method of administration

 

Table 3: Ramucirumab dose reductions for proteinuria

 

Initial ramucirumab dose:

First dose reduction to:

Second dose reduction to:

8 mg/kg

6 mg/kg

5 mg/kg

10 mg/kg

8 mg/kg

6 mg/kg

 

 

Permanent discontinuation

 

Dose reductions for individual components of FOLFIRI may be made for specific toxicities. Dose modifications of each component of FOLFIRI should be made independently and are provided in Table 4. Table 5 provides details of dose delays or dose reductions of components of FOLFIRI at the next cycle based on maximum grade of specific adverse eventsdrug reactions.

 

Table 5: Dose modification of FOLFIRI components due to specific AEDRs [Minor changes to table 5]

 

*The 28 day time period begins on day 1 of the cycle subsequent to the AEDR.

 

Cyramza is for intravenous use.

 

4.4             Special warnings and precautions for use

 

Traceability

In order to improve traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

 

 

Sodium restricted diet

Each 10 ml vial contains less than 1 mmol sodium (23 mg), that is to say essentially ‘sodium free’. Each 50 ml vial contains approximately 85 mg sodium. This is equivalent to approximately 4% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

 

Sodium restricted diet

Each 10 ml vial contains less than 1 mmol sodium (23 mg), that is to say essentially ‘sodium free’. Each 50 ml vial contains approximately 85 mg sodium. This is equivalent to approximately 4% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

 

 

4.6          Fertility, pregnancy and lactation

 

Breast-feeding

It is unknown whether ramucirumab is excreted in human milk. Excretion in milk and oral absorption is expected to be low. As a risk to breast‑fed newborns/infants cannot be excluded, breast-feeding should be discontinued during treatment with Cyramza and for at least 3 months after the last dose. 

 

 

4.7             Effects on ability to drive and use machines

 

Cyramza has no or negligible influence on the ability to drive and use machines.no known influence on the ability to drive and use machines. If patients experience symptoms affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.

 

4.8          Undesirable effects

 

c    Based on study RAINBOW (ramucirumab plus paclitaxel). Includes: leukopenia and white blood cell count decreased.

 

5.1          Pharmacodynamic properties

 

Gastric cancer:

 

6.4             Special precautions for storage

 

(2 ºC to-8 ºC-).

 

In case of prefilled intravenous infusion container usage

Based on the calculated volume of ramucirumab, remove the corresponding volume of sodium chloride 9 mg/ml (0.9%) solution for injection from the prefilled 250 ml intravenous container. Aseptically transfer the calculated volume of ramucirumab to the intravenous container. The final total volume in the container should be 250 ml. The container should be gently inverted to ensure adequate mixing. Do not freeze or shake DO NOT FREEZE OR SHAKE the infusion solution. Do notDO NOT dilute with other solutions or co-infuse with other electrolytes or medicinal products.

 

In case of empty intravenous infusion container usage

Aseptically transfer the calculated volume of ramucirumab into an empty intravenous infusion container. Add a sufficient quantity of sodium chloride 9 mg/ml (0.9%) solution for injection to the container to make the total volume 250 ml. The container should be gently inverted to ensure adequate mixing. Do not freeze or shake DO NOT FREEZE OR SHAKE the infusion solution. Do notDO NOT dilute with other solutions or co-infuse with other electrolytes or medicinal products.

9.         DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

 

               Date of first authorisation: 19 December 2014

               Date of latest renewal: 26 September 2019

 

10.      DATE OF REVISION OF THE TEXT

 

               01 August 201926 September 2019

 

 

CZ7MCZ8M

 

              

 

Updated on 8 August 2019 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - dose and frequency
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 7 August 2019 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.1             Therapeutic indications   

Gastric cancer

Colorectal cancer

Non-small cell lung cancer

Hepatocellular carcinoma

Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.

4.2             Posology and method of administration

Hepatocellular carcinoma (HCC)

The recommended dose of ramucirumab as a single agent is 8 mg/kg every 2 weeks.

Alpha fetoprotein (AFP) testing in HCC

Patients with HCC should be selected based on a serum AFP concentration of ≥ 400 ng/ml with a validated AFP test prior to ramucirumab treatment (see section 5.1).

Hepatic encephalopathy or hepatorenal syndrome (see section 4.4).

There is no relevant use of ramucirumab in the paediatric population for the indications of advanced gastric cancer or gastro-oesophageal adenocarcinoma, adenocarcinoma of the colon and rectum lung carcinoma, and hepatocellular carcinoma.

 

4.4             Special warnings and precautions for use

For HCC patients with evidence of portal hypertension or prior history of oesophageal variceal bleeding, screening for and treatment of oesophageal varices should be performed as per standard of care before starting ramucirumab treatment.

Hepatic impairment

Ramucirumab should be used with caution in patients with severe liver cirrhosis (Child-Pugh B or C), cirrhosis with hepatic encephalopathy, clinically significant ascites due to cirrhosis, or hepatorenal syndrome. There are very limited efficacy and safety data available in these patients. In these patients, rRamucirumab should only be used in these patients if the potential benefits of treatment are judged to outweigh the potential risk of progressive hepatic failure.

In HCC patients, hepatic encephalopathy was reported at a higher rate in the ramucirumab-treated patients compared to the placebo-treated patients (see section 4.8). Patients should be monitored for clinical signs and symptoms of hepatic encephalopathy. Ramucirumab should be permanently discontinued in the event of hepatic encephalopathy or hepatorenal syndrome (see section 4.2).

4.8             Undesirable effects

Tables 6 and 7 below list the adverse drug reactions (ADRs) from placebo controlled phase  III clinical trials associated with ramucirumab used either as a monotherapy treatment for gastric cancer and HCC or in combination with different chemotherapy regimens for the treatment of gastric cancer, mCRC and NSCLC. Adverse Drug Reactions (ADRs) which were reported in patients with advanced gastric cancer, mCRC or NSCLC are listed below by MedDRA body system organ class, frequency and grade of severity. The following convention has been used for classification of frequency:

Gastric cancer

Ramucirumab in combination with paclitaxel

The following table provides the frequency and severity of ADRs based on results from RAINBOW, a phase 3 study in adult patients with advanced gastric cancer randomised to treatment with ramucirumab in combination with paclitaxel or placebo plus paclitaxel.

Table 6: ADRs reported in patients treated with ramucirumab as monotherapy in phase 3 clinical trials (REGARD, REACH-2 and REACH patients with alpha fetoprotein ≥ 400 ng/ml)

in ≥5% of ramucirumab treated patients in RAINBOW

System Organ Class (MedDRA)

Very Common

Common

Uncommon

Blood and lymphatic system disorders

Thrombocytopeniaa

Neutropeniaa

 

Metabolism and nutrition disorders

 

Hypokalaemiaa,b

Hyponatraemiaa

Hypoalbuminaemiaa

 

Nervous system disorders

Headache

Hepatic encephalopathyc

 

Vascular disorders

Hypertensiona,d

Arterial thromboembolic eventsa

 

Respiratory, thoracic, and mediastinal disorders

 

Epistaxis

 

Gastrointestinal disorders

Abdominal paina,e

Diarrhoea

Intestinal obstructiona

Gastrointestinal perforationa

Skin and subcutaneous tissue disorders

 

Rasha

 

Renal and urinary disorders

Proteinuriaa,f

 

 

General disorders and administration site disorders

Peripheral oedema

Infusion-related reactionsa

 

a             Terms represent a group of events that describe a medical concept rather than a single event or preferred term.

b             Includes: hypokalaemia and blood potassium decreased.

c             Based on study REACH-2 and REACH (single-agent ramucirumab in HCC). Includes hepatic encephalopathy and hepatic coma.

d             Includes: blood pressure increased and hypertension.

e             Includes: abdominal pain, abdominal pain lower, abdominal pain upper, and hepatic pain.

f              Includes one case of nephrotic syndrome

Table 7: ADRs reported in patients treated with ramucirumab in combination with chemotherapy in phase 3 clinical trials (RAINBOW, REVEL and RAISE)

System Organ Class (MedDRA)

Very Common

Common

Infections and infestations

 

Sepsisa,b

Blood and lymphatic system disorders

Neutropeniaa

Leukopeniaa,c

Thrombocytopeniaa

Febrile neutropeniad

Metabolism and nutrition disorders

 

Hypoalbuminaemiaa

Hyponatraemiaa

Vascular disorders

Hypertensiona,e

 

Respiratory, thoracic, and mediastinal disorders

Epistaxis

 

Gastrointestinal disorders

Stomatitis

Diarrhoea

Gastrointestinal haemorrhage eventsa,f

Gastrointestinal perforationa

Skin and subcutaneous tissue disorders

 

Palmar-plantar erthyrodysaesthesia syndromeg

Renal and urinary disorders

Proteinuriaa,h

 

General disorders and administration site disorders

Fatiguea,i

Mucosal inflammationd

Peripheral oedema

 

a             Terms represent a group of events that describe a medical concept rather than a single event or preferred term.

b             Based on study RAINBOW (ramucirumab plus paclitaxel).

c             Based on study RAINBOW (ramucirumab plus paclitaxel). Includes: leukopenia and white cell count decreased.

d             Based on study REVEL (ramucirumab plus docetaxel).

e             Includes: blood pressure increased, hypertension, and hypertensive cardiomyopathy.

f              Based on study RAINBOW (ramucirumab plus paclitaxel) and study RAISE (ramucirumab plus FOLFIRI). Includes: anal haemorrhage, diarrhoea haemorrhage, gastric haemorrhage, gastrointestinal haemorrhage, haematemesis, haematochezia, haemorrhoidal haemorrhage, Mallory‑Weiss syndrome, melaena, oesophageal haemorrhage, rectal haemorrhage, and upper gastrointestinal haemorrhage.

g             Based on study RAISE (ramucirumab plus FOLFIRI).

h             Includes cases of nephrotic syndrome.

i              Based on study RAINBOW (ramucirumab plus paclitaxel) and study REVEL (ramucirumab plus docetaxel). Includes: fatigue and asthenia.

System organ class

Frequency

ADR

Cyramza

plus

paclitaxel

(N=327)

Placebo

plus

paclitaxel

(N=329)

All grades toxicity

(%)

Grade ≥3

toxicity

(%)

All grades toxicity

(%)

Grade ≥3

toxicity

(%)

Blood and lymphatic system disorders

Very common

Neutropenia

54.4

40.7

31.0

18.8

Very common

Leukopenia

33.9

17.4

21.0

6.7

Very common

Thrombocytopenia

13.1

1.5

6.1

1.8

Metabolism and nutrition disorders

Very common

Hypoalbuminaemia

11.0

1.2

4.9

0.9

Vascular disorder

Very common

Hypertensiona

25.1

14.7

5.8

2.7

Respiratory, thoracic, and mediastinal disorders

Very common

Epistaxis

30.6

0.0

7.0

0.0

Gastrointestinal disorders

Very common

Gastrointestinal haemorrhage eventsb

10.1

3.7

6.1

1.5

Very common

Stomatitis

19.6

0.6

7.3

0.6

Very common

Diarrhoea

32.4

3.7

23.1

1.5

Renal and urinary disorders

Very common

Proteinuria

16.8

1.2

6.1

0.0

General disorders and administration site disorders

Very common

Fatigue/Asthenia

56.9

11.9

43.8

5.5

Very common

Peripheral oedema

25.1

1.5

13.7

0.6

a             Includes hypertensive cardiomyopathy.

b             MedDRA preferred terms included anal haemorrhage, diarrhoea haemorrhage, gastric haemorrhage, gastrointestinal haemorrhage, haematemesis, haematochezia, haemorrhoidal haemorrhage, Mallory‑Weiss syndrome, melaena, oesophageal haemorrhage, rectal haemorrhage, and upper gastrointestinal haemorrhage.

 

Clinically relevant ADRs reported in ≥1% and <5% of the ramucirumab plus paclitaxel-treated patients in RAINBOW were gastrointestinal perforation (1.2% ramucirumab plus paclitaxel versus 0.3% for placebo plus paclitaxel) and sepsis (3.1% ramucirumab plus paclitaxel versus 1.8% placebo plus paclitaxel).

 

Ramucirumab as a single agent

The following table provides the frequency and severity of the ADRs based on results from REGARD, a phase 3 study in adult patients with advanced gastric cancer randomised to treatment with single-agent ramucirumab plus Best Supportive Care (BSC) or placebo plus BSC.

 

Table 7: ADRs reported in ≥5% of ramucirumab treated patients in REGARD

 

System organ class

Frequency

ADRa,b

Cyramza

(N=236)

Placebo

(N=115)

All gradesc toxicity

(%)

Grade 3-4 toxicity

(%)

All grades toxicity

(%)

Grade 3-4 toxicity

(%)

Metabolism and nutrition disorders

Common

Hypokalaemiad

5.9

2.1

5.2

0.9

Common

Hyponatraemia

5.5

3.4

1.7

0.9

Nervous system disorders

Common

Headache

9.3

0

3.5

0

Vascular disorders

Very common

Hypertensione

16.1

7.6

7.8

2.6

Gastrointestinal disorders

Very common

Abdominal painf

28.8

5.9

27.8

2.6

Very common

Diarrhoea

14.4

0.8

8.7

1.7

a             MedDRA preferred term (Version 15.0)

b             There were no Grade 5 ADRs for Cyramza. There was one Grade 4 ADR of hypokalaemia and one of hyponatraemia.

c             Refer to NCI CTCAE Criteria (Version 4.0) for each Grade of toxicity.

d             MedDRA preferred terms included are: blood potassium decreased and hypokalaemia.

e             MedDRA preferred terms included are: blood pressure increased and hypertension.

f              MedDRA preferred terms included are: abdominal pain, abdominal pain lower, abdominal pain upper, and hepatic pain.

 

Clinically relevant ADRs reported in ≥1% and <5% of the ramucirumab treated patients in REGARD were: neutropenia, arterial thromboembolic events (see sections 4.2 and 4.4), intestinal obstruction, epistaxis, and rash.

 

Clinically relevant reactions (including Grade ≥3) associated with antiangiogenic therapy observed in ramucirumab-treated patients across clinical studies were: gastrointestinal perforations, infusion-related reactions and proteinuria (see sections 4.2 and 4.4).

 

Colorectal cancer

Ramucirumab in combination with FOLFIRI

The following table provides the frequency and severity of the ADRs based on results from RAISE, a phase 3 study in adult patients with mCRC randomised to treatment with ramucirumab plus FOLFIRI or placebo plus FOLFIRI.

 

Table 8: ADRs reported in ≥5% of ramucirumab treated patients in RAISE

 

System organ class

Frequency

ADR

Cyramza

plus

FOLFIRI (N=529)

Placebo

plus

FOLFIRI (N=528)

All grades toxicity

(%)

Grade ≥3

toxicity

(%)

All grades toxicity

(%)

Grade ≥3

toxicity

(%)

Blood and lymphatic system disorders

Very common

Neutropenia

58.8

38.4

45.6

23.3

Very common

Thrombocytopenia

28.4

3.0

13.6

0.8

Metabolism and nutrition disorders

Common

Hypoalbuminaemia

5.9

1.1

1.9

0.0

Vascular disorder

Very common

Hypertension

26.1

11.2

8.5

2.8

Respiratory, thoracic, and mediastinal disorders

Very common

Epistaxis

33.5

0.0

15.0

0.0

Gastrointestinal disorders

Very common

Gastrointestinal haemorrhage events

12.3

1.9

6.8

1.1

Very common

Stomatitis

30.8

3.8

20.8

2.3

Renal and urinary disorders

Very common

Proteinuriaa

17.0

3.0

4.5

0.2

Skin and subcutaneous tissue disorders

Very common

Palmar-plantar erthyrodysaesthesia syndrome

12.9

1.1

5.5

0.4

General disorders and administration site disorders

Very common

Peripheral oedema

20.4

0.2

9.1

0.0

a             Includes cases of nephrotic syndrome.

 

Clinically relevant ADRs reported in ≥1% and <5% of the ramucirumab plus FOLFIRI-treated patients in RAISE: gastrointestinal perforation (1.7% ramucirumab plus FOLFIRI versus 0.6% for placebo plus FOLFIRI).

 

Colorectal cancer

 

Ramucirumab in combination with FOLFIRI

 

NSCLC

Ramucirumab in combination with docetaxel

The following table provides the frequency and severity of the ADRs based on results from REVEL, a phase 3 study in adult patients with NSCLC randomised to treatment with ramucirumab in combination with docetaxel or placebo plus docetaxel.

 

Table 9: ADRs reported in ≥5% of ramucirumab treated patients in REVEL

 

System Organ Class

Frequency

ADR

Cyramza

plus

docetaxel

(N=627)

Placebo

plus

docetaxel

(N=618)

All grades toxicity

(%)

Grade

3-4 toxicity

(%)

All grades toxicity

(%)

Grade

3-4 toxicity

(%)

Blood and lymphatic system disorders

Very common

Febrile neutropenia

15.9

15.9

10.0

10.0

Very common

Neutropenia

55.0

48.8

46.0

39.8

Very common

Thrombocytopenia

13.4

2.9

5.2

0.6

Vascular disorders

Very common

Hypertension

10.8

5.6

4.9

2.1

Respiratory, thoracic, and mediastinal disorders

Very common

Epistaxis

18.5

0.3

6.5

0.2

Gastrointestinal disorders

Very common

Stomatitis

23.3

4.3

12.9

1.6

General disorders and administration site disorders

Very common

Fatigue/Asthenia

54.7

14.0

50.0

10.5

Very common

Mucosal inflammation

16.1

2.9

7.0

0.5

Very common

Peripheral oedema

16.3

0

8.6

0.3

 

Clinically relevant ADRs reported in ≥1% and <5% of the ramucirumab plus docetaxel‑treated patients in REVEL were hyponatraemia (4.8% ramucirumab plus docetaxel versus 2.4% for placebo plus docetaxel), proteinuria (3.3% ramucirumab plus docetaxel versus 0.8% placebo plus docetaxel) and gastrointestinal perforation (1% ramucirumab plus docetaxel versus 0.3% placebo plus docetaxel).

 

5.1       Pharmacodynamic properties

Efficacy results are shown in Table 108.

Table 108: Summary of efficacy data – Intent to treat (ITT) population

Efficacy results are shown in Table 119.

Table 119: Summary of efficacy data – ITT population

Efficacy results are shown in Table 1210 and Figures 4 and 5.

Table 1210: Summary of efficacy data – ITT population

Efficacy results are shown in Table 1311.

Table 1311: Summary of efficacy data – ITT population

Hepatocellular carcinoma

REACH-2

REACH-2 was a global, randomised, double-blind study of Cyramza plus BSC versus placebo plus BSC that randomised (2:1) 292 patients with HCC who had a serum AFP ≥ 400 ng/ml at study entry. Patients enrolled into the study had disease progression on or after prior sorafenib therapy or were intolerant to sorafenib. Eligible patients were Child Pugh A (score < 7), had creatinine clearance ≥ 60 ml/min, and ECOG PS of 0 or 1. In addition, patients were either Barcelona Clinic Liver Cancer (BCLC) stage B and no longer amenable to locoregional therapy, or were BCLC stage C. Patients with brain metastases, leptomeningeal disease, uncontrolled spinal cord compression, a history of or current hepatic encephalopathy or clinically meaningful ascites, severe variceal bleeding in the 3 months prior to treatment, or gastric or oesophageal varices at high risk of bleeding were excluded from the study. The primary endpoint was overall survival. The threshold for the elevated AFP study entry requirement for REACH-2 was determined based on the survival results from a pre-specified subgroup, exploratory analysis from REACH, a previously completed, supportive phase 3 clinical study in 565 HCC patients randomised (1:1) to either Cyramza plus BSC or placebo plus BSC that had disease progression on or after prior sorafenib therapy.

 

In REACH-2, baseline patient demographics and disease characteristics were generally balanced between arms, except for AFP, which was lower in the placebo arm. Patients treated with Cyramza experienced a statistically significant improvement in OS, compared to placebo (Table 12). The major efficacy outcome in REACH-2 was supported by a statistically significant improvement in progression free survival in Cyramza treated patients compared to placebo treated patients. The relative treatment effect (assessed by HR) of Cyramza compared to placebo was generally consistent across subgroups, including age, race, aetiology of disease and reason for discontinuation of sorafenib (progressive disease vs. intolerance). A relevant exposure-efficacy association was observed for ramucirumab in REACH-2 (see section 5.2). REACH-2 efficacy results are shown in Table 12 and Figure 8.

Table 12: Summary of efficacy data in REACH-2 – Intent to treat (ITT) population

 

Cyramza

N=197

Placebo

N=95

Overall survival, months

   Median (95% CI)

8.51 (7.00, 10.58)

7.29 (5.42, 9.07)

   Hazard ratio (95% CI)

0.710 (0.531, 0.949)

   Stratified log-rank p-value

0.0199

Progression free survival, months

   Median (95% CI)

2.83 (2.76, 4.11)

1.61 (1.45, 2.69)

   Hazard ratio (95% CI)

0.452 (0.339, 0.603)

   Stratified log-rank p-value

<0.0001

Objective Response Rate (CR + PR)

   ORR % (95% CI)

4.6 (1.7, 7.5)

1.1 (0.0, 3.1)

   p-value

0.1697

       

Abbreviations: CI = confidence interval, CR = complete response, ORR = objective response rate and PR = partial response

Figure 8: Kaplan-Meier curves of Overall Survival for Cyramza versus placebo in REACH-2

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with Cyramza in all subsets of the paediatric population in gastric adenocarcinoma, in adenocarcinoma of the colon and rectum, and in lung carcinoma, and liver cancer (see section 4.2 for information on paediatric use).

5.2      Pharmacokinetic properties

Following the dose regimen of 8 mg/kg every 2 weeks, the geometric means of ramucirumab Cmin prior to administration of the fourth and seventh dose of ramucirumab given as a single agent in advanced gastric cancer patients’ serum were 49.5 μg/ml (range of 6.3-228 μg/ml) and 74.4 μg/ml (range of 13.8-234 μg/ml), respectively. In HCC patients’ serum the geometric means of ramucirumab Cmin prior to administration of the second, fourth and seventh dose of ramucirumab were 23.5 μg/ml (range of 2.9‑76.5 μg/ml), 44.1 μg/ml (range of 4.2‑137 μg/ml) and 60.2 μg/ml (range of 18.3‑123 μg/ml), respectively. prior to administration of the fourth and seventh dose, respectively of ramucirumab given as a single agent, in serum from patients with advanced gastric cancer.

Other special populations

Based on PopPK, the following covariates were found to have no impact on ramucirumab disposition: age, sex, race, body weight, albumin levels. These and other factors investigated had < 20 % effect on ramucirumab disposition. Body weight is considered a significant co-variate of ramucirumab pharmacokinetics supporting the dosing based on body weight.

Exposure response relationships

Efficacy

Exposure-response analyses indicated that efficacy was correlated with ramucirumab exposure across pivotal studies. Efficacy, as measured by improvements in OS and PFS, was associated with increasing ramucirumab exposure range produced by 8 mg/kg ramucirumab given every 2 weeks and by 10 mg/kg ramucirumab given every 3 weeks. An improvement in PFS was also associated with increasing ramucirumab exposure for advanced gastric cancer, NSCLC, and mCRC.

In the REACH-2 study for HCC, a relevant exposure-efficacy association was observed for ramucirumab which showed that only patients with above-median exposure experienced an improvement in OS, compared to placebo, and these exposure-efficacy relationships remained after attempts to adjust for other prognostic factors. A treatment effect on PFS was observed for all exposure levels produced by 8 mg/kg ramucirumab given every 2 weeks.

In the pooled data from REACH-2 and REACH (patients with alpha fetoprotein ≥ 400 ng/ml), the incidences of Grade ≥ 3 hypertension was increased with higher ramucirumab exposure.

10.      DATE OF REVISION OF THE TEXT

04 April 201901 August 2019

 

CZ6MCZ7M

Updated on 29 May 2019 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 29 May 2019 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.8             Undesirable effects                          

Adverse reactions from other sources

ADRs of haemangioma and thrombotic microangiopathy were reported in ramucirumab clinical trials at a frequency of common (1.5%) and rare (0.03%), respectively, and through post-marketing reporting.

...                          

Website: www.mhra.gov.uk/yellowcard Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

 

10.      DATE OF REVISION OF THE TEXT

20 September 201804 April 2019

Updated on 8 November 2018 PIL

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 17 October 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 17 October 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes

Added (underline), deleted (strikethrough), additional notes:

CYRAMZA®
 

4.2       Posology and method of administration

Special populations 

Elderly patients

In the pivotal studies there is limited evidence that patients 65 years of age or older are at increased risk of adverse events compared to patients younger than 65 years old…

RPatients with renal impairment

There have been no formal studies with Cyramza in patients with renal impairment…

HPatients with hepatic impairment

There have been no formal studies with Cyramza in patients with hepatic impairment…

 

4.4       Special warnings and precautions for use

Sodium restricted diet

Each 10 ml vial contains less than 1 mmol sodium (23 mg), that is to say essentially ‘sodium free’. Each 50 ml vial contains approximately 85 mg sodium. This is equivalent to approximately 4% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Each 10 ml vial contains approximately 17 mg sodium and each 50 ml vial contains approximately 85 mg sodium. To be taken into account for patients on a sodium restricted diet.

 

5.2       Pharmacokinetic properties

Elderly patients

Based on PopPK, there was no difference in ramucirumab exposure in patients ≥65 years of age compared to patients <65 years old.

 

10.     DATE OF REVISION OF THE TEXT

20 September 201825 January 2016

Updated on 16 February 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 16 February 2016 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



The SPC has been extensively updated, with the main change relating to the addition of two new indications in section 4.1:

Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.

Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.

In association with these new indications, new or changed text, has been introduced into sections 4.2, 4.3, 4.4, 4.5, 4.8, 5.1, 5.2 and 10.

Separately, further changes have been made to 4.4, 5.2 and 9.

Updated on 11 February 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 11 February 2016 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to date of revision
  • Change to dosage and administration
  • Change to MA holder contact details

Updated on 15 January 2016 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes

Added (bold), Deleted (strikethrough):

 

 

 

10      MARKETING AUTHORISATION HOLDER

 

Eli Lilly Nederland B.V.
Grootslag 1‑5
NL‑3991 RA, Houten
Papendorpseweg 83
3528 BJ Utrecht
The Netherlands

 

 

10.     DATE OF REVISION OF THE TEXT

 

31 August 201501 January 2015

Updated on 12 January 2016 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 23 September 2015 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes

Added (bold, underlined), Deleted (strikethrough):

 

 

5.       PHARMACOLOGICAL PROPERTIES

 

5.1       Pharmacodynamic properties

 

Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies ATC code: Not yet assignedL01XC21.

 

 

10.     DATE OF REVISION OF THE TEXT

 

19 December 2014 31 August 2015

Updated on 6 February 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 February 2015 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided